DUBLIN, June 14, 2022 /PRNewswire/ -- The "Axial Spondyloarthritis Market - A Global and Country Analysis: Focus on Commercialized Therapies, Potential Pipeline Products, Indication, and Country - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.
The global axial spondyloarthritis market was estimated to be at $1,873.8 million in 2021, which is expected to grow with a CAGR of 13.44% and reach $7,937.8 million by 2032. The growth in the global axial spondyloarthritis market is expected to be driven by the introduction of novel products, the increasing awareness about the disease, and the rising research and development investments, among others. The global axial spondyloarthritis market is well established. Biopharmaceutical companies are trying to match themselves with new technologies in the market to improve the overall system from drug discovery to drug commercialization. The companies operating in the global axial spondyloarthritis market are now focusing more on biologics and personalized therapy to enhance therapeutics and improve patient outcomes. Drug development is more prominent in countries such as the U.S., Germany, and the U.K. Moreover, the presence of major market players such as UCB S.A., Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer, Inc., Eli Lilly and Company, and Novartis International AG in seven major countries, including the U.S., EU4 (Germany, France, Spain, Italy) and U.K., and Japan have a positive impact on the market growth. Potential Pipeline Products (Anti-Janus Kinase (JAK) Therapy, Anti-Interleukin (IL)-17 Therapy, Other Therapy) Country (U.S., Germany, France, U.K., Italy, Spain, Japan)
The U.S. axial spondyloarthritis market was valued at $1,231.2 million in 2021 and is the leading market contributor. The growth can be attributed to the increased research and development activities in the country. 1.1.3 Inclusion and Exclusion
1.4.2 Current Market Size and Growth Potential, $Million, 2021-2032
1.4.5.2 Assessment of SpondyloArthritis international Society (ASAS) and European League Against Rheumatism (EULAR) Recommendations
1.4.8.1 Interruption in Research and Clinical Development and Commercial Operation
1.4.8.1.1 Research and Clinical Development
1.4.8.1.2 Commercial Operation and Access
1.4.8.2 Navigating Crisis Recovery and Looking to the Future
2.2 Legal Requirements and Frameworks in the U.S.
2.2.1 Clinical Trial Authorization
2.2.2 Marketing Authorization
2.2.3 U.S. Food and Drug Administration Guidelines for Biologics License Application (BLA)
2.2.4 Post-Authorization Regulations
2.3 Legal Requirements and Frameworks in Europe
2.5 Reimbursement and Cost Analysis
3.3.1 The Introduction of Novel Products
3.3.2 Increasing Awareness About the Disease
3.3.3 Rising Research and Development Investments
3.4.1 High Treatment Cost Impacting the Adoption Rate
3.4.2 Increased Delay in Diagnosis
3.5.1 Massive Scope in Emerging Markets
4.2 Key Developments and Strategies
4.3 Market Share Analysis, by Company (2021)
4.4 Growth Share Analysis
5.2.2.1.1 Simponi as Subcutaneous Formulation 5.2.2.1.2 Simponi AREA as an Intravenous Formulation 8.1.1 Commercialized Products in the U.S.
8.1.2 Commercialized Products in EU4 + U.K.
For more information about this report visit https://www.researchandmarkets.com/r/5fy1vu
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Fax (outside U.S.): +353-1-481-1716